Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib.

Blood Cancer J · 2022 · PMC9024068 · PMID 35459222

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

a trend towards significancep = 0.07so close (0.05 < p ≤ 0.1)

Vaccine type also showed a trend towards significance with superior anti-S IgG response observed in those receiving BNT162b2 (MV OR = 6, 95% CI: 0.85–48.57, p = 0.07, Fig. 2 ).

also in 2,760 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.